Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556022 · ClinicalTrials.gov registry record · Phase 2
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
A Phase 2 study, sponsored by Cytori Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01556022 is a Phase 2 study that has completed, run by Cytori Therapeutics. The registered enrollment target is 28 participants.
The verdict
NCT01556022, a Phase 2 study, has completed, sponsored by Cytori Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a prospective, randomized, placebo-controlled, double blind safety and feasibility clinical trial.
Interventions
- DEVICE ADRCs processed by the Celution System
- DEVICE Placebo Comparator: Lactated Ringer's and Subject's Blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01556022
The ClinicalTrials.gov registry entry for NCT01556022 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytori Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ADRCs processed by the Celution System is the first listed.
NCT01556022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01556022 about?
NCT01556022 is a clinical study titled "Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia". This is a prospective, randomized, placebo-controlled, double blind safety and feasibility clinical trial.
What is the current status of trial NCT01556022?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2012-06. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01556022?
The interventions under investigation include: ADRCs processed by the Celution System (DEVICE), Placebo Comparator: Lactated Ringer's and Subject's Blood (DEVICE).
Who is sponsoring clinical trial NCT01556022?
This trial is sponsored by Cytori Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.